<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635912/" ref="ordinalpos=2570&amp;ncbi_uid=4829972&amp;link_uid=PMC3635912" image-link="/pmc/articles/PMC3635912/figure/F4/" class="imagepopup">Figure 4.  From: Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K <span class="highlight" style="background-color:">signaling</span> <span class="highlight" style="background-color:">pathway</span> independently of Akt phosphorylation. </a></div><br /><div class="p4l_captionBody"><b>PI3-K signaling pathway is involved in </b><b>anoikis </b><b>resistance phenotype conferred by Timp1.</b> The MaGFP and MaT1S cell lines were treated overnight with PI3-K inhibitors, Wortmannin (<b>A</b>) or LY294002 (<b>B</b>), and their clonogenic capability was evaluated. <b>C.</b> Melan-a melanocytes stably transfected with GFP (control transfection, MaGFP) and Timp1 (MaT1S) were maintained in suspension for 1, 3, 5 and 24 hours. The Akt activation was assessed by Western blotting. *p &lt; 0.05, **p &lt; 0.01, ****p &lt; 0.0001.</div></div>